Valsartan Optimal Therapy Against Elevated Home Blood Pressure Research（VOYAGER）Study

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare improvement percentage of urinary albumin excretion between valsartan 80 mg- and valsartan 160 mg-based therapy in patient with morning hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kitakyushu-Tsuyazaki Hospital
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Outpatients aged over 20 years and less than 80 years, regardless of sex.

• Patients with stable seated morning home blood pressure of over 135 mmHg and/or diastolic blood pressure of over 85 mmHg within 1 to 2 weeks.

• Patients who are on therapy with conventional dosage of ARB.

Exclusion Criteria:

• Patients who are difficult to measure home blood pressure.

• Patients with secondary hypertension or malignant hypertension.

• Patients with seated systolic blood pressure of over 200 mmHg.

• Patients with seated diastolic blood pressure of over 120 mmHg.

• Patients with a history of cerebrovascular disorder or myocardial infarction or heart failure within 6 months prior to enrolment in the study.

• Patients with atrial fibrillation, atrial flutter, or serious arrhythmia.

• Patients with renal dysfunction with serum creatinine level of over 2 mg/dL.

• Patients with serious liver dysfunction.

• Patient with HbA1C of over 8 percent.

• Patient with positive albuminuria by dip and read stick test.

• Patient treated with any angiotensin converting enzyme inhibitor

• Pregnant women

• Patients with a history of hypersensitivity to valsartan.

• Other patients who are judged to be inappropriate for the study by the investigator or sub-investigator.